Oncternal Therapeutics Future Growth
Future criteria checks 0/6
Oncternal Therapeutics's earnings are forecast to decline at 13.8% per annum while its annual revenue is expected to grow at 2.6% per year. EPS is expected to grow by 1.5% per annum.
Key information
-13.8%
Earnings growth rate
1.5%
EPS growth rate
| Biotechs earnings growth | 31.3% |
| Revenue growth rate | 2.6% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 08 Mar 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1 | -56 | N/A | -52 | 1 |
| 12/31/2025 | 1 | -48 | N/A | -44 | 2 |
| 12/31/2024 | 0 | -34 | N/A | -39 | 3 |
| 12/31/2023 | 1 | -39 | -32 | -32 | N/A |
| 9/30/2023 | 1 | -42 | -35 | -35 | N/A |
| 6/30/2023 | 1 | -43 | -41 | -41 | N/A |
| 3/31/2023 | 1 | -46 | -39 | -39 | N/A |
| 12/31/2022 | 1 | -44 | -37 | -37 | N/A |
| 9/30/2022 | 2 | -41 | -34 | -34 | N/A |
| 6/30/2022 | 4 | -39 | -29 | -29 | N/A |
| 3/31/2022 | 4 | -35 | -29 | -29 | N/A |
| 12/31/2021 | 4 | -31 | -27 | -27 | N/A |
| 9/30/2021 | 5 | -26 | -24 | -24 | N/A |
| 6/30/2021 | 4 | -21 | -23 | -23 | N/A |
| 3/31/2021 | 4 | -18 | -19 | -19 | N/A |
| 12/31/2020 | 3 | -17 | -17 | -17 | N/A |
| 9/30/2020 | 3 | -19 | -17 | -17 | N/A |
| 6/30/2020 | 2 | -19 | -15 | -15 | N/A |
| 3/31/2020 | 3 | -37 | -17 | -17 | N/A |
| 12/31/2019 | 2 | -34 | -17 | -17 | N/A |
| 9/30/2019 | 2 | -31 | -16 | -16 | N/A |
| 6/30/2019 | 2 | -28 | -12 | -12 | N/A |
| 3/31/2019 | 3 | -7 | -7 | -7 | N/A |
| 12/31/2018 | 3 | -7 | -7 | -7 | N/A |
| 12/31/2017 | 2 | -10 | -9 | -9 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GTU is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GTU is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GTU is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GTU's revenue (2.6% per year) is forecast to grow slower than the German market (5.4% per year).
High Growth Revenue: GTU's revenue (2.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GTU's Return on Equity is forecast to be high in 3 years time